亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

医学 合并分析 彭布罗利珠单抗 肿瘤科 肺癌 内科学 免疫疗法 癌症 荟萃分析 放射治疗
作者
Willemijn S.M.E. Theelen,Dawei Chen,Vivek Verma,Brian P. Hobbs,Heike Peulen,Joachim G.J.V. Aerts,Idris Bahce,Anna Larissa N. Niemeijer,Joe Y. Chang,Patricia M. de Groot,Quynh-Nhu Nguyen,Nathan Comeaux,George R. Simon,Ferdinandos Skoulidis,Steven H. Lin,Kewen He,Roshal R. Patel,John V. Heymach,Paul Baas,James W. Welsh
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (5): 467-475 被引量:573
标识
DOI:10.1016/s2213-2600(20)30391-x
摘要

Summary

Background

Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab) with or without radiotherapy. When the trials were analysed individually, a potential benefit was noted in the combination treatment arm. However, owing to the small sample size of each trial, differences in response rates and outcomes were not statistically significant but remained clinically notable. We therefore did a pooled analysis to infer whether radiotherapy improves responses to immunotherapy in patients with metastatic non-small-cell lung cancer.

Methods

Inclusion criteria for the PEMBRO-RT and MDACC trials were patients (aged ≥18 years) with metastatic non-small-cell lung cancer and at least one unirradiated lesion to monitor for out-of-field response. In the PEMBRO-RT trial, patients had previously received chemotherapy, whereas in the MDACC trial, patients could be either previously treated or newly diagnosed. Patients in both trials were immunotherapy-naive. In the PEMBRO-RT trial, patients were randomly assigned (1:1) and stratified by smoking status (<10 vs ≥10 pack-years). In the MDACC trial, patients were entered into one of two cohorts based on radiotherapy schedule feasibility and randomly assigned (1:1). Because of the nature of the intervention in the combination treatment arm, blinding to radiotherapy was not feasible in either trial. Pembrolizumab was administered intravenously (200 mg every 3 weeks) with or without radiotherapy in both trials. In the PEMBRO-RT trial, the first dose of pembrolizumab was given sequentially less than 1 week after the last dose of radiotherapy (24 Gy in three fractions), whereas in the MDACC trial, pembrolizumab was given concurrently with the first dose of radiotherapy (50 Gy in four fractions or 45 Gy in 15 fractions). Only unirradiated lesions were measured for response. The endpoints for this pooled analysis were best out-of-field (abscopal) response rate (ARR), best abscopal disease control rate (ACR), ARR at 12 weeks, ACR at 12 weeks, progression-free survival, and overall survival. The intention-to-treat populations from both trials were included in analyses. The PEMBRO-RT trial (NCT02492568) and the MDACC trial (NCT02444741) are registered with ClinicalTrials.gov.

Findings

Overall, 148 patients were included in the pooled analysis, 76 of whom had been assigned pembrolizumab and 72 who had been assigned pembrolizumab plus radiotherapy. Median follow-up for all patients was 33 months (IQR 32·4–33·6). 124 (84%) of 148 patients had non-squamous histological features and 111 (75%) had previously received chemotherapy. Baseline variables did not differ between treatment groups, including PD-L1 status and metastatic disease volume. The most frequently irradiated sites were lung metastases (28 of 72 [39%]), intrathoracic lymph nodes (15 of 72 [21%]), and lung primary disease (12 of 72 [17%]). Best ARR was 19·7% (15 of 76) with pembrolizumab versus 41·7% (30 of 72) with pembrolizumab plus radiotherapy (odds ratio [OR] 2·96, 95% CI 1·42–6·20; p=0·0039), and best ACR was 43·4% (33 of 76) with pembrolizumab versus 65·3% (47 of 72) with pembrolizumab plus radiotherapy (2·51, 1·28–4·91; p=0·0071). Median progression-free survival was 4·4 months (IQR 2·9–5·9) with pembrolizumab alone versus 9·0 months (6·8–11·2) with pembrolizumab plus radiotherapy (hazard ratio [HR] 0·67, 95% CI 0·45–0·99; p=0·045), and median overall survival was 8·7 months (6·4–11·0) with pembrolizumab versus 19·2 months (14·6–23·8) with pembrolizumab plus radiotherapy (0·67, 0·54–0·84; p=0·0004). No new safety concerns were noted in the pooled analysis.

Interpretation

Adding radiotherapy to pembrolizumab immunotherapy significantly increased responses and outcomes in patients with metastatic non-small-cell lung cancer. These results warrant validation in a randomised phase 3 trial.

Funding

Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
勤劳的翩跹完成签到,获得积分10
8秒前
yc发布了新的文献求助10
25秒前
1分钟前
1分钟前
1分钟前
我是笨蛋完成签到 ,获得积分10
1分钟前
欣喜的人龙完成签到 ,获得积分10
1分钟前
无花果的应助被荷兰香猪采纳,获得10
1分钟前
炙热芒果完成签到 ,获得积分10
1分钟前
1分钟前
荷兰香猪发布了新的文献求助10
1分钟前
传奇3的应助被药石无医采纳,获得10
2分钟前
2分钟前
Hello的应助被或大或小采纳,获得10
2分钟前
药石无医发布了新的文献求助10
2分钟前
传统的艳完成签到,获得积分10
2分钟前
荷兰香猪发布了新的文献求助10
2分钟前
zhangnan完成签到 ,获得积分10
2分钟前
荷兰香猪完成签到,获得积分10
2分钟前
2分钟前
lay完成签到,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
3分钟前
Owen的应助被科研通管家采纳,获得10
3分钟前
mimi完成签到 ,获得积分10
3分钟前
故意的梦琪完成签到,获得积分10
3分钟前
3分钟前
hugeyoung完成签到,获得积分10
3分钟前
盼盼发布了新的文献求助10
4分钟前
盼盼完成签到,获得积分10
4分钟前
ramsey33完成签到 ,获得积分10
4分钟前
酷酷云朵完成签到,获得积分10
4分钟前
4分钟前
帅气忻完成签到 ,获得积分10
5分钟前
5分钟前
SCI的芷蝶完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190148
求助须知:如何正确求助?哪些是违规求助? 9577257
关于积分的说明 21852289
捐赠科研通 7788541
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560044
邀请新用户注册赠送积分活动 2482880